Statistical Programming

When you require accurate and efficient statistical programming CRO services, MMS is your first choice.

When faced with an urgent delivery, MMS knocked it out of the park. This Biometrics team is one of the best I’ve worked with.
Head of Biometrics
Large Pharma Sponsor

Sponsors come to MMS statistical programming experts for three things: accuracy, innovation, and knowledge. A deep bench ensures that knowledge flows throughout the project team and cross-functionally for strong datasets, analyses, and other outputs. Resulting from this is fewer drafts, a smoother review process, and time saved for every Sponsor.

Programming Innovation & Quality
Along with expertise in SAS & R our experienced team has the advantage of proprietary tools and AI, to aid in the efficiency and automation of programming deliverables.
 
Complete Support
Comprehensive support across the entire drug development lifecycle, including Phase I-IV clinical trials, 120-day safety updates, AD-Hoc requests, HTA, RWE, BIMO, integrated summary of Safety/Efficacy (ISS/ISE, data anonymization), and SEND datasets.
 
Data Integration & Standardization
Creation of CDISC compliant SDTM/ADaM datasets and specifications, including legacy data conversion to industry standards and up-compliance for legacy data if needed. Creation of analysis tables, listings, and figures (TLFs), planned, ad-hoc, and/or rescue to the highest standards.
 
Submission Readiness         
Submission readiness for the creation of submission-ready datasets and specifications, annotated CRFs, define files, and reviewers’ guides.

Services Provided
  • Creation of CDISC-compliant SDTM and ADaM datasets
  • Generate planned and ad-hoc analysis TLFs
  • Data anonymization
  • SEND dataset and submission package support as per FDA requirement
  • Development of submission ready define files, reviewers guide
  • Support and recommendation for Bioresearch Monitoring (BIMO) package
  • Validation and gap analyses
  • Data Safety Monitoring Board (DSMB) support, Development Safety Update Report (DSUR) support, advisory committees, and IND reporting
  • Open communication within and across functions driving higher levels of success
Immutable Tables

MMS programmers using proprietary technology are proficient at creating immutable tables which have several in-text applications for the MMS writing team and sponsors including but not limited to:

  • increased efficiency and quality
  • streamlined QC processes, and
  • early messaging discussions, among others.
Exceptional Quality & Efficiency

At MMS, every programmed deliverable (e.g. dataset, TFL, documentation) follows a three-phase process of quality control, validation and assurance, ensuring that we deliver to the highest standards.Exceptional Quality & Efficiency

Rescue Studies

MMS Statistical programming is specialized in the review and assessment of all study elements and identifying key issues that could be preventing study success.

Study rescue plans focus on resolving current bottlenecks and study challenges by introducing new strategies, such as expediting study schedules or finding other solutions to regain time and momentum.

Rescue studies are often challenging for any CRO, but MMS has been trusted with a considerable number of rescue studies by its sponsors with consistent success.

Suggested For You

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium

perspectives

November 26th, 2024

Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs 

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year